Therapeutic Treatment

Abstract

This invention discloses a treatment for a patient receiving medication to treat an attention deficit disorder such as ADHD wherein the treatment results in a loss of appetite and impairment of the patient's attentiveness. The treatment combines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases the caloric intake of a patient, which can increase the patient's attentiveness. The combination treatment can be given for an indefinite, including, without limitation, life-long, to allow a patient to maintain normal caloric intake during treatment for an attention deficit disorder.

What is claimed is: 
     
         1 . A method of reducing a loss of attentiveness in an individual suffering from an attention deficit disorder, wherein the method reduces the CGI-I by a reduction in the score by 1 or more and further, wherein the individual's CGI-S score is reduced by at least 15% and attentiveness is increased by at least 10% as compared to a patient taking only methylphenidate by administering to the patient in the morning a pharmaceutical composition comprising methylphenidate and cyproheptadine and wherein the pharmaceutical composition maintains mean peak plasma for at least 6 hours. 
     
     
         2 . The method of reducing a loss of attentiveness of  claim 1 , wherein the CGI-S score is reduced by at least 20%. 
     
     
         3 . The method of reducing a loss of attentiveness of  claim 1 , wherein the CGI-S score is reduced by at least 25%. 
     
     
         4 . The method of reducing a loss of attentiveness of  claim 1 , wherein the CGI-S score is reduced by at least 40%. 
     
     
         5 . The method of reducing a loss of attentiveness of  claim 1 , wherein the CGI-S score is reduced by about 10% to about 80%. 
     
     
         6 . The method of reducing a loss of attentiveness of  claim 1 , wherein the CGI-S score is reduced by about 10% to about 90%. 
     
     
         7 . The method of reducing a loss of attentiveness of  claim 1 , wherein the CGI-S score is reduced by about 20% to about 70%. 
     
     
         8 . The method of reducing a loss of attentiveness of  claim 1 , wherein the individual shows improvement in at least one of the following measures of attentiveness, the p academic performance rating scale, ADD evaluation scale-3rd edition (ADDES-3),ADHD rating scale-IV (ADHD-RS-IV), youth self report (broadband instrument), Conners parent rating scale-revised (CPRS-R), Conners teacher rating scale-revised (CTRS-R), Conners 3 self-reporting scale (Conner 3-SR; ages 8-18 y), home situa-tions questionnaire-revised, inattention/overactivity with aggression (IOWA) Conners teacher's rating scale, Swanson Nolan and Pelham IV scale (SNAP-IV), Swanson Kotkin Agler M-Flynn and Pelham (SKAMP), Vanderbilt ADHD diagnostic parent rating scale (VADPRS), Vanderbilt ADHD diagnostic teacher rating scale (VADTRS), behavior assess-ment system for children-2nd edition (BASC-2) or the Con-ners rating scale long version. 
     
     
         9 . The method of reducing a loss of attentiveness of  claim 1 , wherein the CGI-S score is reduced by 1 or more as compared to a patient receiving methylphenidate alone. 
     
     
         10 . The method of reducing a loss of attentiveness of  claim 1 , wherein the mean peak plasma level is maintained through lunch following administration in the morning.